Turning Scientific Promise Into Innovation
Acadia (acadia.com) scores 83 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, in the 89th percentile of 19686 Healthcare brands.
Acadia is a biopharmaceutical company focused on developing treatments for underserved neurological disorders and rare diseases. It targets complex therapeutic areas where few or no treatment options currently exist, including conditions such as Parkinson's Disease Psychosis and Rett Syndrome. The company positions itself as addressing urgent, unmet patient needs by advancing innovative medicines for these difficult-to-treat conditions, serving patients, families, and the healthcare providers who treat them.
| Brand Name | Acadia |
|---|---|
| Domain | acadia.com |
| Industry | Healthcare |
| Main Competitors | Ionis Pharmaceuticals (79/100), BioMarin Pharmaceutical (84/100), Neurocrine Biosciences (82/100), Jazz Pharmaceuticals (82/100), Sarepta Therapeutics (83/100), PTC Therapeutics (85/100), Supernus Pharmaceuticals (78/100), Alkermes (80/100) |
Moz Domain Authority 47/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Acadia appears on Wikipedia but without a dedicated company entity, so AI models can confuse it with similarly named subjects.
The homepage meta description reads "Acadia advances care for underserved neurological disorders and rare diseases. Since our founding, we have been working at the forefront of healthcare to bring vital solutions to p…" (Meta description: 32 words. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram, GitHub; no detected presence on YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Acadia?", Claude could identify the brand as of October 2026. ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders, best known for Nuplazid (pimavanserin), approved for hallucinations and delusions associated with Parkinson's disease psychosis. Best known for Developing Nuplazid, the first FDA-approved treatment for Parkinson's disease psychosis.
When asked "Best brands similar to Acadia?", Claude would recommend Acadia as of October 2026. It's a recognized name in CNS-focused biopharma and would come up naturally alongside similar specialty pharmaceutical companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Acadia's main competitors in Healthcare: Ionis Pharmaceuticals (79/100), BioMarin Pharmaceutical (84/100), Neurocrine Biosciences (82/100), Jazz Pharmaceuticals (82/100), Sarepta Therapeutics (83/100).
Sources: Brand Analyzer scan
Acadia has limited AI-search visibility, scoring 40/100 on Brand Analyzer's AI visibility composite (visibility 33, trust 43, recommendation 50). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Acadia official site
Acadia scores 50/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Acadia official site
Acadia is a biopharmaceutical company that develops treatments for underserved neurological disorders and rare diseases, focusing on conditions where few or no treatment options currently exist.
Sources: Acadia official site
Acadia develops and brings to market innovative medicines for complex, underserved therapeutic areas, including treatments for conditions like Parkinson's Disease Psychosis and Rett Syndrome. The company works to bring vital treatment solutions to patients who have limited existing options.
Sources: Acadia official site
Acadia can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Acadia official site
Acadia's treatments are intended for patients and families affected by underserved neurological disorders and rare diseases, such as those with Parkinson's Disease Psychosis or Rett Syndrome, as well as the healthcare providers who diagnose and treat these conditions.
Sources: Acadia official site
Acadia is known for developing treatments targeting underserved neurological disorders and rare diseases, specifically addressing conditions such as Parkinson's Disease Psychosis and Rett Syndrome, areas where few or no other treatment options exist.
Sources: Acadia official site
Acadia scores 40/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Acadia has a limited AI-visibility profile at 40/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (50/100) and its weakest is visibility (33/100). It benefits from a Wikidata knowledge-graph entry, a Moz Domain Authority of 47/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Acadia from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Acadia: American College of Allergy, Asthma and Immunology (ACAAI) (83/100), AbbVie (83/100), American Chiropractic Association (ACA) (83/100), Accreditation Commission for Health Care (ACHC) (83/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.